Current plasmid technology manufacturing is both expensive and low yielding, which presents significant challenges for any application where cost-of-goods is a factor. That’s where the BPE technology comes in.

The BPE plasmid technology is a high yielding, ultra-low cost, selection marker free plasmid technology developed by Pegasus Biotech. BPE uses a novel bacterial origin combined with a genetically modified e. coli to drive ultra-high yields in an antimicrobial free environment. Both the origin and genetically modified bacteria are made up of intellectual property owned by Pegasus Biotech. Replication of the plasmid is thermoregulated, allowing us to maximize fermentation yields.

The BPE backbone is small enough to allow optimal transfection efficiency, which enables Chrysaor to use less DNA per vaccine to get the same punch. The minimized prokaryotic sequences allow for uninhibited transcription of our target of interest, along with easier lipidation and translocation to the nucleus. Every single nucleotide of the plasmid has been curated for purpose.

Chrysaor has developed its own antigen targets for vaccine manufacturing and efficacy testing. Chrysaor uses unique modifications of our vaccine epitopes to better generate immunity against the selected target. Chrysaor generates the novel antigens used in the veterinary vaccines. Every aspect of the target is designed to optimize the immune response, allowing enhanced protection to the pathogen.